Anthem Biosciences IPO enters Day 2; should you subscribe?

The initial public offering (IPO) of Anthem Biosciences has entered its second day today, Tuesday. On the first day of bidding, the issue was subscribed 0.73 times, with investors placing bids for 3.21 crore shares against 4.40 crore shares available, as per BSE data.

Before the IPO opened, the company allotted 1.78 crore shares to 60 anchor investors at Rs 570 each, which is the highest price in the IPO range.

Anthem Biosciences IPO: Should you apply? Here's what Anil Singhvi suggests

Zee Business Managing Editor Anil Singhvi has given a positive view on the IPO. He advised investors to apply for both listing gains and to hold the stock for 2-3 years as a long-term investment. “Apply for good listing gain and long term. This stock should be in your pharma portfolio for 2-3 years,” he said.

Also Read: Anthem Biosciences raises Rs 1,016 crore from anchor investors ahead of IPO 

What works in company’s favour:

• Experienced and professional promoters
• Market leader in CRDMO (contract research and manufacturing)
• Track record of successful drugs
• Long-term relationships with clients
• Strong financials, positive cash flow, and very low debt
• Better financials compared to listed competitors
• While smaller than Divi’s Laboratories in size, it matches in quality

Risks and concerns:

• Heavy dependence on one client (Davos Pharma contributes 14 per cent of revenue)
• R&D spending has been falling
• Growth depends on the success of new drug molecules
• Valuation is fair — not too cheap, not too expensive

Anthem Biosciences IPO details: Price, lot size, and financial performance

This IPO is an Offer for Sale (OFS), meaning the money raised will go to existing promoters and investors, not the company. The price band has been set at Rs 540 to Rs 570 per share. Investors can apply for a lot of 26 shares and in multiples of that.

In terms of financials, the company posted a 30 per cent rise in revenue from Rs 1,419 crore in FY24 to Rs 1,844 crore in FY25. Net profit also increased by 23 per cent to Rs 451 crore.

Industry competitors

Anthem Biosciences operates in the pharma and biotech space. Its listed peers include Sai Life Sciences, Syngene International, Suven Life Sciences, and Divi’s Laboratories.